Resources

Adeyinka et al. (2025). Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models.

Carhart-Harris et al. (2018). Psilocybin and the essential importance of context.

Carhart-Harris et al. (2016). The entropic brain: a theory of conscious states informed by psilocybin research with psychedelic drugs.

Catlow et al. (2013). Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning.

Choi et al. (2024). Mechanisms of psilocybin on the treatment of posttraumatic stress disorder.

Davis et al. (2023). Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD.

Doblin et al. (2019). The past and future of psilocybin science: an introduction to this issue.

Healy et al. (2025). Acute subjective effects of psychedelics in naturalistic group settings prospectively predict longitudinal improvements in trauma symptoms, trait shame, and connectedness among adults with childhood maltreatment histories

Khan et al. (2022). Psilocybin for trauma-related disorders: a systematic review.

Krediet et al. (2020). Reviewing the potential of psilocybin for the treatment of PTSD.

Ly et al. (2018). Psilocybin promotes structural and functional neural plasticity.

MacCallum et al. (2022). Therapeutic use of psilocybin: Practical considerations for dosing and administration.

Mehmood et al. (2025). Ceremonial Psychedelic Experiences and Changes in Mental Health Outcomes in Those with Adverse Childhood Experiences

Modlin et al. (2025). Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework.

Parikh et al. (2026). Neuroplastogen Treatment for Posttraumatic Stress Disorder

Schenberg (2018). Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.

Watts et al. (2017). Patients' accounts of increased "connectedness" and "acceptance" after psilocybin for treatment-resistant depression.

Carhart-Harris et al. (2021). Trial of Psilocybin versus Escitalopram for Depression.

Carhart-Harris et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Dagnino et al. (2026). Distinct brain responses to psilocybin and escitalopram in depression captured by the Fluctuation-Dissipation Theorem.

Davis et al. (2020). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.

Davis et al., (2025). Five-year outcomes of psilocybin assisted therapy for Major Depressive Disorder.

Fabiano et al. (2026). The combination of exercise and psychedelics for the treatment of major depressive disorder.

Frautschi et al. (2021). Multimodal neuroimaging of the effect of serotonergic psychedelics on the brain.

Goldberg et al. (2020). The experimental effects of psilocybin on symptoms and anxiety and depression: a meta-analysis. 

Goodwin et al. (2023). Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.

Goodwin et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.

Griffiths et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Gukasyan et al. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.

Haikazian et al. (2023). Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.

Harding et al. (2025). Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises

Jungwirth et al. (2024). Psilocybin increases emotional empathy in patients with major depression.

Jungwirth et al. (2026). Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational Study

Kaczmarek et al. (2026). Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression.

Kishi et al. (2026). Psilocybin-assisted therapy for major depressive disorder: Perspective from meta-analysis

Ko et al. (2023). Psychedelic therapy for depressive symptoms: a systematic review and meta-analysis.

Mertens et al. (2026). Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial

Mertens. et al. (2026). Efficacy and Safety of Psilocybin in Treatment-Resistant Major DepressionThe EPISODE Randomized Clinical Trial

Raison et al. (2023). Single-Dose Psilocybin Treatment for Major Depressive disorder: A Randomized Clinical Trial.

Roseman et al. (2018). Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.

Rucker et al. (2022). Psilocybin & the psychedelic drugs. Past, present & future.

Siegel et al. (2024). Psilocybin desynchronizes the human brain.

Sloshower et al. (2024). Psychological flexibility as a mechanism of change in psilocybin‑assisted therapy for major depression: results from an exploratory placebo‑controlled trial.

Syed et al. (2026). Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis.

Teodoro Andrade et al. (2025). Therapeutic Use of Psilocybin in Depression: a Systematic Review of Clinical Evidence.

Thomas et al. (2017). Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.

von Rotz et al. (2022). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomized clinical trial.

Watts (2021). The Psilocybin for Depression: The ACE Manual.

Watts & Luoma (2020). The use of the psychological therapy flexibility model to support psychedelic assisted therapy.

Weintraub et al. (2026). Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial

Williams, Barnett & Szigeti (2026). Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding ConditionsA Systematic Review and Meta-Analysis

Yngwe et al. (2026). Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major DepressionA Randomized Clinical Trial

Zeifman et al. (2021). Rapid and sustained decreases in suicidality following a single dose of psilocybin among individuals with recurrent major depressive disorder.

Ziff et al. (2022). Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review.

Bogenschutz et al. (2022). Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.

Bogenschutz & Forcehimes (2016). Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism.

Carhart-Harris & Goodwin (2015). The therapeutic potential of psilocybin: past, present, and future.

Griffiths et al. (2017). Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.

Glynos et al. (2024). Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey.

Grieco et al. (20222). Psychedelics and Neural Plasticity: Therapeutic Implications.

Hendricks et al. (2026). Psilocybin in the Treatment of Cocaine Use DisorderA Randomized Clinical Trial

Hendricks et al. (2015). Psilocybin use is associated with reduced psychological distress and suicidality in the United States adult population.

Johnson et al. (2026). Psilocybin or Nicotine Patch for Smoking CessationA Pilot Randomized Clinical Trial

Johnson et al. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation.

Johnson et al. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Mackey et al. (2022). Evidence Brief: Psychedelic Medications for Mental Health and Substance Use Disorders.

Nichols (2016). Psychedelics.

Noorani et al. (2018). Psilocybin therapy for smoking cessation: Qualitative study of participant accounts.

Piper et al. (2024). Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.

Qeadan et al. (20250. Associations between psychedelic use and adverse outcomes in substance use disorders: a real-world EHR-based cohort study.

Urban et al. (2026). Epigenome-wide association study of psilocybin-induced methylome changes in alcohol use disorder

van der Meer et al. (2023). Therapeutic effect of psilocybin in addiction: a systematic review.

Vanderijst et al. (2024). Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial.

Winkelman (2014). Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca.

Zafar et al. (2023). Psychedelic therapy in the treatment of addiction: the past, present and future.

Argento et al. (2022). Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.

Argento et al. (2019). The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis.

Bassir Nia et al. (2025). The Contribution of Psychotherapy in Potential Therapeutic Effects of Psychedelics for Treatment of Opioid Use Disorder.

Brett et al. (2023). Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder.

Floris et al. (2025). Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats.

Hornick & Stefanski (2023). Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder.

Jones (2025). Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder.

Jones et al. (2022). Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample.

Johl (2023). Approaches to Treat Opioid Use and Concurrent Mental Health Disorders in Canada: An Exploratory Analysis of Psychedelic-Assisted Psychotherapy.

Kimble & Coustasse (2025). The Promise of Psilocybin-Assisted Therapy for Opioid Use Disorder.

Lee et al. (2024). Opioid use disorder: current trends and potential treatments.

Nicholas et al. (2023). Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings.

Piper et al. (2024). Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.

Pulido-Saavedra et al. (2025). Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies.

Szpak et al. (2025). Views on Psychedelic-Assisted Therapy for Substance Use Disorders from Individuals with Opioid Use Disorder and a History of Injection-Related Infections: A Qualitative Study.

van der Meer et al. (2023). Therapeutic effect of psilocybin in addiction: a systematic review.

Weleff et al. (2024). From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder.

Zafar et al. (2023). Psychedelic therapy in the treatment of addiction: the past, present and future.

Ziff et al. (2022). Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review.

Agin-Liebes et al. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.

Barrett et al. (2020). Emotions and brain function are altered up to one month after a single high dose of psilocybin.

Goel & Zilate (2022). Potential Therapeutic Effects of Psilocybin: A Systematic Review.

Goldberg et al. (2020). The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.

Griffiths et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Grob et al. (2011). Pilot study of psilocybin treatment of anxiety in patients with advanced-stage cancer.

Harari et al. (2024). Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor.

Hasler et al. (2004). Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.

Hood & Elkins (2026). Effect of psilocybin-assisted psychotherapy on anxiety symptoms: A systematic review and meta-analysis

Kraehenmann et al. (2012). Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.

Ly et al. (2018). Psilocybin promotes structural and functional neural plasticity.

Ross et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Wittmann et al. (2007). Effects of psilocybin on time perception and temporal control of behaviour in humans.

van Elk & Yaden (2022). Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review.

Agin-Liebes et al. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.

Barimbing et al. (2026). Efficacy of psilocybin on death anxiety in terminal patients: a narrative review

Barrett & Griffiths (2018). Classic hallucinogens and mystical experiences: phenomenology & neural correlates.

Belser et al. (2017). Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis.

Griffiths et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Grob et al. (2011). Pilot study of psilocybin treatment of anxiety in patients with advanced-stage cancer.

Guss et al. (2020). The Yale manual for psilocybin-assisted therapy of depression (using acceptance and commitment therapy as a therapeutic frame).

Kim et al. (2024). Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application—a review.

Konstantinou et al. (2026). Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety.

Malone et al. (2024). Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy.

Ross et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Sweeney et al. (2022). Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying.

Swift et al. (2017). Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress.

Ziff et al. (2022). Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review.

Beesley et al. (2025). Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement.

Carhart-Harris et al. (2018). Psilocybin and connectedness.

Ehrenkranz et al. (2024). Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder.

Gonzalez et al. (2022). Restorative Retelling for Processing Psychedelic Experiences: Rationale and Case Study of Complicated Grief.

Lebedev et al. (2015). Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin.

Low & Earlywine (2024). Psychedelic Experiences After Bereavement Improve Symptoms of Grief: The Influence of Emotional Breakthroughs and Challenging Experiences.

Palitsky et al. (2023). Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted Therapies.

Rosenbaum et al. (2018). The Use of Psychedelics for Grief Following Death due to Advanced Illness: A Scoping Review.

Sabucedo et al. (2024). Psychedelic-assisted grief therapy: a mixed-method case study.

Brownstien et al. (2024). Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming.

Buot et al. (2023). Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey.

Ching et al. (2023). Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled trial.

Collins (2024). Psychedelics for the Treatment of Obsessive–Compulsive Disorder: Efficacy and Proposed Mechanisms.

Ehrmann et al. (2022). Psilocybin for the Treatment of Obsessive-Compulsive Disorders.

Graziosi et al. (2024). Psychedelics, OCD and related disorders: A systematic review.

Gattuso et al. (2025). Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence.

Jacobs (2020). A potential role for psilocybin in the treatment of obsessive-compulsive disorder.

Ly et al. (2018). Psilocybin promotes structural and functional neural plasticity relevant to OCD.

Moreno et al. (2026). A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder

Moreno et al. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.

Owe-Larsson et al. (2024). Psilocybin in pharmacotherapy of obsessive-compulsive disorder.

Pellegrini et al. (2025). Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study.

Szafoni et al. (2024). Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder.

Wilcox (2014). Psilocybin and Obsessive Compulsive Disorder.

Yang et al. (2025). Psilocybin and Obsessive-Compulsive Disorder: Exploring New Therapeutic Horizons.

Ammineni & Park (2025). The compulsive eating paradigm: can psychedelics help in treating obesity?

Bevione et al. (2025). Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials.

Borgland & Neyens (2022). Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies.

Bryson et al. (2024). Established and emerging treatments for eating disorders.

Calder et al. (2023). Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms.

Conn et al. (2024). Psilocybin restrains activity-based anorexia in female rats by enhancing cognitive flexibility: contributions from 5-HT1A and 5-HT2A receptor mechanisms.

Cuerva et al. (2024). Perspectives and preliminary experiences of psychedelics for the treatment of eating disorders: A systematic scoping review.

Dallery et al. (2026). An open-label pilot study of psilocybin-assisted therapy for binge eating disorder.

Downey et al. (2024). Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians.

Downey et al. (2023). “But the reality is it's happening”: A qualitative study of eating disorder providers about psilocybin-assisted psychotherapy.

Gukasyan et al. (2022). Psychedelic-Assisted Therapy for People with Eating Disorders.

Hu et al. (2025). Psychedelics and Eating Disorders: Exploring the Therapeutic Potential for Anorexia Nervosa and Beyond.

Koning et al. (2024). Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design.

Lacroix et al. (2024). Psychedelics and the treatment of eating disorders: considerations for future research and practice.

Lafrance et al. (2024). Beyond the numbers: reimagining healing with psychedelics for eating disorders.

Ledwos et al. (2023). Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder.

Loh & Luke (2025). Exploring the Role of Psychedelic Experiences on Wellbeing and Symptoms of Disordered Eating.

Morris et al. (2026). Understanding experiences of psychedelic treatments for eating disorders: a meta-synthesis of qualitative studies

Otterman (2023). Research into Psychedelic-Assisted Psychotherapy for Anorexia Nervosa Should be Funded.

Peck et al. (2023). Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study.

Rodan et al. (2025). Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED–FED survey.

Aday et al. (2025). Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial.

Askey et al. (2026). Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia

Askey et al. (2024). Psilocybin as a novel treatment for chronic pain.

Bhanot et al. (2023). A systematic review to assess the use of psilocybin in the treatment of headaches.

Brendstrup-Brix et al. (2026). Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache

Brengel et al. (2025). Psilocybin as a Treatment for Repetitive Mild Head Injury: Evidence from Neuroradiology and Molecular Biology

Davenport (2016). Psychedelic and nonpsychedelic LSD and psilocybin for cluster headache.

Garcia-Romeo et al. (2026). Pilot study of psilocybin in patients with post-treatment lyme disease.

Goel et al. (2023). Use of Psychedelics for Pain: A Scoping Review.

Gojani et al. (2026). Serotonergic psychedelics as epigenetic modulators: A paradigm shift in Alzheimer's disease therapeutics

Henderson et al. (2025). Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights.

Im & Sandoe (2025). Psychedelics and Headache Disorders: an Update.

Jevotovsky et al. (2024). Psilocybin and chronic neuropathic pain: a systematic review.

Johnson et al. (2012). Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.

Kargbo (2021). Psychedelic Therapeutic: Potential Treatment for Headache Disorders.

Kooijman et al. (2023). Are psychedelics the answer to chronic pain: A review of current literature.

Lago et al. (2026). Transient multidomain functional improvement in advanced Alzheimer’s disease following high-dose psilocybin-containing mushroom administration: a case report

Lawrence (2023). Self-administration of Psilocybin for the Acute Treatment of Migraine: A Case Report.

Leighton et al. (2025). Clinical treatment of cluster headache with the serotonergic indoleamine psychedelics psilocybin and LSD and with ketamine: A case series.

Lu et al. (2026). Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus

Madsen et al. (2022). Psilocybin-induced reduction in chronic cluster headache attack frequency correlates with changes in hypothalamic functional connectivity.

Robinson et al. (2024). Scoping Review: The Role of Psychedelics in the Management of Chronic Pain.

Rucker et al. (2023). Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study.

Schindler et al. (2025). Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial.

Schindler et al. (2024). Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial.

Schindler & Sico (2023). Studying classic psychedelics for the management of headache disorders: Considerations for Veterans.

Schindler & Hendricks (2023). Adapting psychedelic medicine for headache and chronic pain disorders.

Schindler et al. (2022). Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial.

Schindler (2022). Psychedelics as preventive treatment in headache and chronic pain disorders.

Schinder et al. (2021). Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin.

Strand et al. (2025). Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management.

VanderZwaag et al. (2026). Psychedelics for the management of symptoms of traumatic brain injury: Findings from the global psychedelic survey.

VanderZwaag et al. (2025). Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery.

Whelan et al. (2020). Public Opinion on the Use of Psychedelics in the Treatment of Cluster Headache.

Whelan & Johnson (2018). Lysergic acid diethylamide (LSD) and Psilocybin for the Management of Patients with Persistent Pain: A Potential Role?

Yerubandi et al. (2024). Acute Adverse Effects of Therapeutic Doses of Psilocybin A Systematic Review and Meta-Analysis.

Zheng et al. (2024). Psilocybin for the treatment of Alzheimer’s disease

Zia et al. (2023). Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.

Ziff et al. (2022). Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review.

Note: Research on psilocybin specifically for autism is extremely limited. Most studies examine other psychedelics or are theoretical papers.

Adamsen et al. (2014). Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene.

Ascone et al. (2026). Classic psychedelics and autism spectrum disorder: preclinical evidence, mechanistic insights and unresolved challenges

Autistic Psychedelic Community

Brumback et al. (2018). Identifying specific prefrontal neurons that contribute to autism-associated abnormalities in physiology and social behavior.

Chen et al. (2024). Autism, youth suicide, and psychedelics: A review of the 21st century evidence.

Danforth (2022). Psychedelic-Assisted Therapy for Social Adaptability in Autistic Adults.

Danforth (2018). Embracing Neurodiversity in Psychedelic Science: A Mixed-Methods Inquiry into the MDMA Experiences of Autistic Adults.

Duerler et al. (2020). LSD-induced increases in social adaptation to opinions similar to one’s own are associated with stimulation of serotonin receptors.

Low (2026). Serotonergic psychedelics for Autism spectrum disorder: Neurobiological mechanisms and translational prospects.

Markopoulos et al. (2022). Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder.

Martin & Nichols (2016). Psychedelics Recruit Multiple Cellular Types and Produce Complex Transcriptional Responses Within the Brain.

Nakamura et al. (2010). Brain serotonin and dopamine transporter bindings in adults with high-functioning autism.

Nuwer (2024). Can psychedelics improve well-being in autism?

Rice (2022). Do autistic people attribute perceived change in mental health to a psychedelic experience?

Stroud et al. (2025). Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey.

Wang et al. (2025). Psychedelics and Pro-Social Behaviors: A Perspective on Autism Spectrum Disorders.

Whelan et al. (2024). The ‘PSILAUT’ protocol: an experimental medicine study of autistic differences in the function of brain serotonin targets of psilocybin.

Note: Research on psilocybin specifically for ADHD is very limited. These are largely theoretical or exploratory studies.

Barrett et al. (2020). Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention.

Barry (2025). Addictive Behavior and Executive Function Following Naturalistic Psilocybin Use.

Carter et al. (2005). Using Psilocybin to Investigate the Relationship between Attention, Working Memory, and the Serotonin 1A and 2A Receptors.

Gattuso et al. (2023). Default mode network modulation by psychedelics: a systematic review.

Haijen et al. (2022). Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: A prospective naturalistic study.

Hutten et al. (2019). Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers.

Kang et al. (2006). Contribution of 5-HT2A receptor gene -1438A>G polymorphism to outcome of attention-deficit/hyperactivity disorder in adolescents.

Kuypers (2024). Microdosing psychedelics in the treatment of ADHD and comorbid disorders.

Milburn (2025). Neuroadaptive Effects of Psilocybin: A Potential Treatment for Adult ADHD.

Totomanova (2020). Psychedelics as a Potential Treatment Option in ADHD.

Note: Research on psilocybin for athletic performance is extremely limited. These citations represent theoretical papers, case studies, news articles and indirect research rather than robust clinical trials.

Aday et al. (2020). Long-term effects of psychedelic drugs: A systematic review. 

Argyri et al. (2026). Learning from boundlessness: epistemic shifts towards a holistic worldview following psychedelic experiences.

Berkovitch et al. (2025). Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans.

Bonnieux et al. (2023). Psilocybin's effects on cognition and creativity: A scoping review.

Calder & Hasler (2022). Towards an understanding of psychedelic-induced neuroplasticity.

Carhart-Harris et al. (2014). The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. 

Catlow et al. (2013). Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning.

Chen & Colonna (2025). Psychedelics reduce fear by targeting immune cells.

Cheng-Teng et al. (2026). Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applications

Chung et al. (2025). Psychedelic control of neuroimmune interactions governing fear.

Fabiano et al. (2026). The combination of exercise and psychedelics for the treatment of major depressive disorder.

Gandy (2019). Psychedelics and potential benefits in “healthy normals”: A review of the literature.

Germann (2020). The Psilocybin-Telomere Hypothesis: An empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging.

Gibson Cook et al. (2026). Psilocybin induces sex- and context-specific recruitment of the stress axis.

Gouttebarge et al. (2019). Occurrence of mental health symptoms and disorders in current and former elite athletes: A systematic review and meta-analysis. 

Griffiths et al. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. 

Hall (2023). New ESPN E60 Examines Use of Psychedelics in Mental Health Treatment of Athletes.

Harding et al. (2025). Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises

Hawryluk & Van Valkenburg (2023). Pain, hope, science collide as athletes turn to magic mushrooms.

Horton et al. (2021). Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy.

Kerr-Gaffney et al. (2026). Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience

Jungaberle et al. (2018). Positive psychology in the investigation of psychedelics and entactogens: A critical review. 

Kahonen (2023). Psychedelic unselfing: self-transcendence and change of values in psychedelic experiences.

Keyes (2002). The mental health continuum: From languishing to flourishing in life. 

Khan et al. (2021). Psychedelics for Brain Injury: A Mini-Review.

Lawrence et al. (2025). Psilocybin Use in an Intercollegiate Athlete with Persisting Symptoms After Concussion: A Case Report.

Lowe et al. (2021). The therapeutic potential of psilocybin.

Lubiano (2024). Going for Gold: Investigating the Benefits of Psychedelics for Athletes.

Ly et al. (2018). Psychedelics Promote Structural and Functional Neural Plasticity.

Machek (2019). Psychedelics: Overlooked Clinical Tools with Unexplored Ergogenic Potential.

MacLean et al. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. 

Mason et al. (2023). Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study.

Mason et al. (2021). Spontaneous and deliberate creative cognition during and after psilocybin exposure.

Mason et al. (2019). Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being.

Meshkat et al. (2024). Impact of psilocybin on cognitive function: A systematic review.

Nardou et al. (2023). Psychedelics reopen the social reward learning critical period.

Neuhaus & Slavich (2022). Behavioral Psychedelics: Integrating Mind and Behavior to Improve Health and Resilience.

Powers (2023). Why serious players are dosing psychedelics like mushrooms and ayahuasca (Golf Digest).

Prochazkova et al. (2018). Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting.

Reiche et al. (2025). Sporadic use of classic psychedelics and neuropsychological performance: A cross-sectional analysis

Rootman et al. (2021). Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.

Semley (2025). Why former NFL All-Pros Are Turning to Psychedelics.

Siegel et al. (2024). Psilocybin desynchronizes the human brain.

Simms (2024). Does Microdosing Improve Athletic Performance?

Teixeira et al. (2021). Psychedelics and health behaviour change.

VanderZwaag et al. (2025). Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery.

Walton & Liknaitzky (2022). Advancing elite athlete mental health treatment with psychedelic-assisted psychotherapy.

Watts & Luoma (2020). The use of the psychological flexibility model to support psychedelic assisted therapy.

1. The VETS program: https://vetsolutions.org/

2. Heroic Hearts Project: https://heroicheartsproject.org/

Armstrong et al. (2022). Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans.

Biscoe et al. (2023). Psilocybin-assisted psychotherapy for the treatment of PTSD in UK armed forces veterans: A feasibility study protocol.

Calnan et al. (2025). Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings.

Catlow et al. (2013). Effects of psilocybin on fear conditioning relevant to veteran PTSD.

Davis et al. (2023). Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD.

Davis et al. (2020). Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans.

Ellis et al. (2025). Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression – A first-in-kind open-label pilot study.

Gray et al. (2023). Beliefs and Perceived Barriers Regarding Psychedelic-assisted Therapy in a Pilot Study of Service Members and Veterans With a History of Traumatic Brain Injury.

Krediet et al. (2020). Reviewing the potential of psilocybin for the treatment of PTSD in veterans.

Ly et al. (2018). Psilocybin promotes neural plasticity relevant to veteran mental health.

Modlin et al. (2025). Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework.

Nutt et al. (2016). Psilocybin and psychiatry: applications for veterans.

Schenberg (2018). Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.

Smith et al. (2022). An Interpretative Phenomenological Analysis of the use of psilocybin by veterans with symptoms of trauma.

Tupper et al. (2015). Psilocybin medicine: applications for veteran populations.

Watts et al. (2017). Veterans' accounts of increased "connectedness" after psilocybin treatment.

Wolfgang et al. (2024). Research and Implementation of Psychedelic-Assisted Therapy in the Veterans Health Administration.

Wolfgang & Hoge (2023). Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations.

Briggs et al. (2026). Does Psychological Flexibility Correlate with Mystical Experiences: A Machine Learning Approach Including State of Surrender, Near-Death Experiences, and Psilocybin Consumption

Brudner et al. (2025). Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression.

Copa et al. (2024). Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity.

Eisner (1997). Set, setting and matrix.

Fincham et al. (2026). An exploratory study of breathwork-induced altered states of consciousness in experienced practitioners: the airways to alteration (A2A) trial

Greenway (2023). Context is a Critical for Psychoactive Drug Effects.

Hultgren et al. (2025). A dose of therapy with psilocybin - A meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy.

Irrmischer et al. (2025). Moderating factors in psilocybin‑assisted treatment affecting mood and personality: A naturalistic, open‑label investigation.

Kajonius et al. (2025). Big Five personality and the psychedelic experience: An initial report.

Levin et al. (2024). The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder.

Modlin et al. (2023). Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation.

Murphy et al. (2022). Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.

O’Mahoney et al. (2026). Trip killers: Addressing a critical knowledge gap in psychedelic research

Robinson et al. (2026) Extended difficulties after psychedelic experiences: Prevalence and associations in a global, multilingual sample

Romeo et al. (2026). Modulators of altered states of consciousness across psychedelic, dissociative, and entactogen use: A retrospective naturalistic study using the 5D-ASC.

Roseman et al. (2018). Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.

Russ et al. (2018). Replication and extension of a model predicting response to psilocybin.

Studerus et al. (2012). Prediction of Psilocybin Response in Healthy Volunteers.

Viljoen et al. (2026). Therapist-rated predictors of response to psychedelic-assisted therapy

Anderson et al. (2020). Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study.

Agrawal et al. (2023). Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder.

Back et al. (2026). Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study.

Burt (2025). Psychedelic-Assisted Groups in the U.S.: A Culturally Responsive Counseling Approach.

Hendricks (2020). Psilocybin-assisted group therapy: A new hope for demoralization.

Hicks et al. (2026). Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study

Kettner et al. (2021). Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness.

Lewis et al. (2023). HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer.

Marseille et al. (2023). Group psychedelic therapy: empirical estimates of cost-savings and improved access.

Ponomarenko et al. (2023). Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors.

Stauffer & Anderson (2024). Psychedelic-assisted group therapy.

Thrul et al. (2023). Innovations in group-based psilocybin-assisted therapy of major depression in patients with cancer.

Trope et al. (2019). Psychedelic-Assisted Group Therapy: A Systematic Review.

Aboulafia-Brakha et al. (2026). Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland

Aday et al. (2026). Major life changes following psychedelic use: A retrospective survey among people using psychedelics naturalistically

Aixala (2024). Deepening Psychedelic Integration: Exploring Complex Settings, Understanding User’s Struggles, and Implementing Safe Interventions.

Bhatt et al. (2026). Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use

Brar et al. (2026). The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential

Breeksema et al. (2022). Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review. 

Bremler et al. (2023). Case analysis of long-term negative psychological responses to psychedelics.

Butler et al. (2026). Characterising the clinical associations of hallucinogen persisting perception disorder: a retrospective cohort study

Carbonaro et al. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Eskinazi et al. (2026). Psychedelic-induced hypomania and mania: a systematic review and meta-analysis

Freitas et al. (2025). The safety of psilocybin-assisted psychotherapy: A systematic review.

Hinkle et al. (2024). Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis.

Johnson et al. (2008). Human Hallucinogen Research: Guidelines for Safety.

Johnson et al. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Johnston et al. (2023). The safety and efficacy of psychedelic-assisted therapies for older adults: knowns and unknowns.

Kettner et al. (2024). Effects of Psychedelics in Older Adults: A Prospective Cohort Study.

McNamee et al. (2023). Studying Harms Is Key to Improving Psychedelic-Assisted Therapy—Participants Call for Changes to Research Landscape.

Nordin et al. (2024). A double-edged sword: Insights from practitioners on the short and long-term negative effects of psilocybin-assisted psychological interventions.

Ona & Bouso (2020). Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: a systematic review.

Palitsky et al. (2024). A framework for assessment of adverse events occurring in psychedelic-assisted therapies.

Perna et al. (2025). Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report.

Pilecki et al. (2021). Ethical and legal issues in psychedelic harm reduction and integration therapy.

Pleet et al. (2023). Reducing the Harms of Nonclinical Psychedelics Use Through a Peer-Support Telephone Helpline.

Roscoe & Lozy (2022). Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials.

Sarparast et al. (2022). Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.

Schruers & Leibold (2025). Psychedelic-assisted psychotherapy: The need to monitor adverse events.

Simonsson et al. (2023). Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis.

Xi et al. (2023). National Institutes of Health psilocybin research speaker series: state of the science, regulatory and policy landscape, research gaps, and opportunities.

Yao et al. (2024). Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.

Yerubandi et al. (2024). Acute Adverse Effects of Therapeutic Doses of Psilocybin A Systematic Review and Meta-Analysis.

Ziff et al. (2022). Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review.

Argento et al. (2022). Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada.

Burt (2025). Psychedelic-Assisted Groups in the U.S.: A Culturally Responsive Counseling Approach.

Celidwen et al. (2023). Ethical principles of traditional Indigenous medicine to guide western psychedelic research and practice.

Cirillo (2025). Current U.S. Approaches to Studying Psychedelic Medicines Compared to Psychedelics Use Among Indigenous Groups: What Are We Missing?

Cornelius (2023). How to fold Indigenous ethics into psychedelics studies.

George et al. (2020). The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion.

Gonzalez-Mariscal & Sosa-Cortes (2022). Insights for Modern Applications of Psilocybin Therapy from a Case Study of Traditional Mazatec Medicine.

Hayes et al. (2022). Will psilocybin lose its magic in the clinical setting?

Manson et al. (2023). Indigenous Voices in Psychedelic Therapy: Experiential Learnings from a Community-Based Group Psychedelic Therapy Program.

McCleave et al. (2024). Traditional and Indigenous Perspectives on Healing Trauma With Psychedelic Plant Medicines.

Michaels et al. (2018). Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature.

Noorani (2021). Containment Matters: Set and Setting in Contemporary Psychedelic Psychiatry.

Palitsky et al. (2025). A Critical Evaluation of Psilocybin-Assisted Therapy Protocol Components From Clinical Trial Patients, Facilitators, and Caregivers.

Palitsky et al. (2023). Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted Therapies.

Petranker et al. (2024). Keeping the promie: a critique of the current state of microdosing research.

Prioleau & Panjwani (2025). Shifting Paradigms: Exploring Multicultural Approaches to Psychedelic-Assisted Therapy in Counseling.

Sebben et al. (2024). Psychedelic medicine and cultural responsiveness: A call for Aboriginal and Torres Strait Islander engagement in Australian clinical trials and practice.

Spiers et al. (2024). Indigenous psilocybin mushroom practices: An annotated bibliography.

Urrutia et al. (2023). Psychedelic Science, Contemplative Practices, and Indigenous and Other Traditional knowledge Systems: Towards Integrative Community-Based Approaches in Global Health.

Williams et al. (2026). Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding ConditionsA Systematic Review and Meta-Analysis

Williams et al. (2022). Indigenous Philosophies and the "Psychedelic Renaissance"

Yaden et al. (2022). Preparing for the Bursting of the Psychedelic Hype Bubble.

Berkovitch et al. (2025). Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans.

Boardman et al. (2026). Personalised Perception: The Effect of Personality on the Sensory Effects of Psychedelics

Carhart-Harris (2026). The entropic brain today

Carhart-Harris (2019). How do psychedelics work?

Carhart-Harris & Goodwin (2017). The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.

Carhart-Harris et al. (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs.

Carhart-Harris et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Chen & Colonna (2025). Psychedelics reduce fear by targeting immune cells.

Cheng-Teng et al. (2026). Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applications.

Chung et al. (2025). Psychedelic control of neuroimmune interactions governing fear.

Di Gregorio et al. (2026). Age moderates the relationship between psychedelics use and mental health in naturalistic settings

Effinger et al. (2026). Sex-specific increased reactivity of the PVT and prolonged PVT→CeA circuit engagement following psilocin administration

Fleury & Nautiyal (2025). The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice.

Garcia-Romeo & Richards (2018). Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.

Garcia-Romeo et al. (2016). Clinical Applications of Hallucinogens: A Review.

Girn et al. (2026). An international mega-analysis of psychedelic drug effects on brain circuit function

Griffiths, Richards & Jesse (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Hartogsohn (2018). The Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity.

Kazdan et al. (2026). Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action

Kettner et al. (2021). Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness.

Knudsen (2022). Sustained effects of single doses of classical psychedelics in humans.

Lyons et al. (2026). Human brain changes after first psilocybin use

Mathai et al. (2025). Shame, Guilt and Psychedelic Experience: Results from a Prospective, Longitudinal Survey of Real-World Psilocybin Use

Mediano et al. (2024). Effects of External Stimulation on Psychedelic State Neurodynamics.

Murray et al. (2026). Network pharmacology and molecular simulation reveal the entourage effect mechanisms of psilocybin-producing mushrooms on the brain

Naddaf (2026, April 6). Your brain on drugs: different psychedelics work in surprisingly similar ways

Nichols (2016). Psychedelics.

Peill et al. (2024). Psychedelics and the ‘inner healer’: Myth or mechanism?

Ramaekers et al. (2025). Not all psychedelics are created equal.

Robinson et al. (2026). Field Notes From Inner Space: Global Psychedelic Survey Participants Report Health Benefits, Personal Growth, and Life Transformations

Rowe et al. (2026). Psychedelic Therapy and the Role of Music: A Scoping Review of Quantitative Evidence on Subjective and Objective Outcomes

Siegel et al. (2024). Psilocybin desynchronizes the human brain.

Sloshower et al. (2024). Psychological flexibility as a mechanism of change in psilocybin‑assisted therapy for major depression: results from an exploratory placebo‑controlled trial.

Soares (2025). Are psychedelic agents ready for prime time as stand-alone treatments?

Syed et al. (2026). Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis

Thomas et al. (2017). Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.

Watts & Luoma (2020). The use of the psychological therapy flexibility model to support psychedelic assisted therapy.

This website provides peer-reviewed research and information about regulated and licensed psilocybin-assisted therapy for educational purposes only. The content, including articles discussing legal, regulatory, and policy matters, does not constitute legal advice and should not be relied upon as such. Laws and regulations regarding psilocybin-assisted therapy vary by jurisdiction and are subject to change. For specific legal guidance, please consult with a licensed attorney in your area.

Barnett et al. (2022). United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.

Brinzei, O. (2025). Clarifying the legal landscape of psilocybin regulation: A medico-legal perspective.

Dixon Ritchie et al. (2023). From prohibited to prescribed: The rescheduling of MDMA and psilocybin in Australia.

Gardner et al. (2019). Psychedelic-assisted therapies: The past, and the need to move forward responsibly.

Goldy et al. (2026). Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones.

Hatfield et al. (2024). A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia.

Heilman, J. E. (2022). The history, legalization, and potentials of psilocybin-assisted psychotherapy.

Lash et al. (2024). Therapeutic implications of psilocybin in the wake of decriminalization.

LeCompte, Z. (2022). Not groovy man: Psilocybin’s long and complicated history with the law, and its potential to treat the growing mental health crisis in America.

Luong et al. (2022). Legal developments in psychedelic therapeutics.

Marks, M. (2023). The varieties of psychedelic law.

Mian, M. et al. (2025). Psychedelic regulation beyond the controlled substances act: A three-dimensional framework for characterizing policy options.

Mocanu et al. (2022). Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy.

Pilecki et al., (2021). Ethical and legal issues in harm reduction and integration therapy.

Schonholz et al. (2024). Legal and ethics concerns of psilocybin as medicine.

Sheppard, B. (2021). A trip through employment law: Protecting therapeutic psilocybin users in the workplace.

Siegel et al. (2024). Psychedelics drug legislative reform and legalization in the US.

Sinha (2024). Regulating the psychedelic renaissance: FDA’s critical role in push for scheduling reform to expand research into psychedelic medicines.

Tremayne-Pengelly (2025, Dec 25). Inside the US’s psychedelic church boom, where taking drugs is legal.

Wolfgang & Hoge (2023). Psychedelic-assisted therapy in military and veterans healthcare systems: Clinical, legal, and implementation considerations.